The American Journal of Medicine
Volume 121, Issue 7 , Pages 604-610 , July 2008

Lowering LDL Cholesterol in Adults: A Prospective, Community-Based Practice Initiative

References 

  1. Summary of the second report on the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
  2. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report on the National Cholesterol Education Program (NCEP) Expert Panel on Detection (Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)). JAMA. 2001;285:2486–2497
  3. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001;22:554–572
  4. Prevention of coronary heart disease in clinical practice (Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention). Eur Heart J. 1998;19:1434–1503
  5. Cardiovascular and metabolic risk factors: how can we improve outcomes in the high risk patient. In: Scott M. Grundy, MD, PhD, Guest Editor. Managing cardio-metabolic risk: will new approaches improve success? Am J Med (Suppl).r 2007;120(9A):S3-S9.
  6. Statins for high-risk patients without heart disease or high cholesterol. Med Lett Drugs Ther. 2006;48(1225):1–3
  7. Crouse J, Elam M, Robinson J, et al. Cholesterol management: targeting a lower low-density lipoprotein cholesterol concentration increases adult treatment panel-III goal attainment. Am J Cardiol. 2006;97(11):1667–1669
  8. Kastelei JJP, Sankatsing RR. Ezetimibe/simvastatin (INEGY) in the treatment of hyperlipidemia. Int J Clin Pract. 2006;59(12):1464–1467
  9. Kermani T, Frishman W. Non-pharmacologic approaches for the treatment of hyperlipidemia. Cardiol Rev. 2005;13(5):247–255
  10. McKenney J. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. Am J Cardiol. 2005;96(4A):60E–66E
  11. Grundy SM. Stano6l esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult treatment Panel III report. Am J Cardiol. 2005;96(1A):47D–50D
  12. Simons LA, Sullivan DR. Lipid-modifying drugs. Med J Aust. 2005;182(6):286–289
  13. Stein EA. Managing dyslipidema in the high-risk patient. Am J Cardiol. 2002;98(5A):50C–57C
  14. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment Project (L-TAP) (A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein goals). Arch Intern Med. 2000;160:459–467
  15. Kannel WB, Larson M. Long-term epidemiologic prediction of coronary disease: the Framingham experience. Cardiology. 1994;82(2-3):137–152
  16. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  17. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (West of Scotland Coronary Prevention Study Group). N Engl J Med. 1995;333(20):1301–1307
  18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  19. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels (Cholesterol and Recurrent Events Trial Investigators). N Engl J Med. 1996;335:1001–1009
  20. The Lipid Research Clinics Coronary Primary Prevention Trial results (I. Reduction in incidence of coronary heart disease). JAMA. 1984;251:351–364
  21. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events, with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study). JAMA. 1998;279:1615–1622
  22. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent CNCEP Writing Group recommendations. Am J Cardiol. 2005;96:556–563
  23. Fonarow GC, Gawlinski A. Rationale of design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles. Am J Cardiol. 2000;85:10A–17A
  24. Birtcher KK, Bowden C, Ballantyne CM, Huyen M. Strategies for implementing lipid-lowering therapy: pharmacy-based approach. Am J Cardiol. 2000;85:30A–35A
  25. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001;87:819–822
  26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  27. Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175–191
  28. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16:343–344
  29. Kaplan NM. The deadly quartet (Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension). Arch Intern Med. 1989;149:1514–1520
  30. Nicholls SJ, Mural Tuzcu E, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary athrosclerosis. JAMA. 2006;297(5):499–508
  31. Genest JJ, McNamara JR, Ordovas JM, et al. Lipoprotein cholesterol, apolipoprotein A-1 and B and lipoprotein (a) abnormalities in men with premature coronary heart disease. J Am Coll Cardiol. 1992;19:792–802
  32. Deedwania PC, Hunninghake DB, Bays H. Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome. Am J Cardiol. 2004;93(11A):18C–26C
  33. Davidson MH. Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome. Am J Cardiol. 2004;93(11A):3C–11C
  34. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med. 2004;164(13):1427–1436
  35. LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435
  36. Ellrodt G, Cook DJ, Lee J, Cho M, Hunt D, Weingarten S. Evidence-based disease management. JAMA. 1997;278(20):1687–1692
  37. Hunter DJ, Fairfield G. Disease management. BMJ. 1997;315:50–52
  38. Weingarten SR, Henning JM, Badamgarav E, et al. Interventions used in disease management programmes for patients with chronic illness—which ones work? (Meta-analysis of published reports). BMJ. 2002;325:925–928
  39. Knight K, Badamgarav E, Henning JM, et al. A systematic review of diabetes disease management programs. Am J Manag Care. 2005;11:242–250
  40. Krause DS. Economic effectiveness of disease management programs: a meta-analysis. Dis Manage. 2005;8:114–134
  41. Ofman JJ, Badamgarava E, Henning JM, et al. Does disease management improve clinical and economic outcomes in patients with chronic diseases? (A systematic review). Am J Med. 2004;117:182–192
  42. Grover SA, Lowensteyn I, Joseph L, et al. Cardiovascular Health Evaluation to Improve Compliance and Knowledge Among Uninformed Patients (CHECK-UP) Study Group (Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP Study: a randomized controlled trial). Arch Intern Med. 2007;167(21):2296–2303

 This initiative was funded by a $20,000 grant from Legacy Health System, Portland, Oregon.

PII: S0002-9343(08)00251-9

doi: 10.1016/j.amjmed.2008.02.031

The American Journal of Medicine
Volume 121, Issue 7 , Pages 604-610 , July 2008

Article Tools

* Image Usage & Resolution